FDA Extends ZymoGenetics’ rhThrombin Action Date To Jan. 17
This article was originally published in The Pink Sheet Daily
Executive Summary
ZymoGenetics and commercialization partner Bayer will use the three-month extension to hone plans for “aggressively converting the market,” firm tells “The Pink Sheet” DAILY.
You may also be interested in...
ZymoGenetics Will Ship Topical Hemostat Recothrom In Two Weeks
Company will price the recombinant, plasma-free thrombin at a 20 percent premium over competitor King's bovine-derived Thrombin JMI.
ZymoGenetics Will Ship Topical Hemostat Recothrom In Two Weeks
Company will price the recombinant, plasma-free thrombin at a 20 percent premium over competitor King's bovine-derived Thrombin JMI.
Johnson & Johnson/Omrix Win General Surgery Hemostasis Approval For Evicel
Approval puts Evicel marginally ahead of ZymoGenetics’ recombinant human fibrin sealant rhThrombin, which has a Jan. 17 action date.